Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2017-08-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the renewal of a steam supply agreement between CSPC XNW and Hebei Hongyuan, which is a connected person under the Listing Rules. It details the terms of the new agreement, historical transaction amounts, proposed annual caps, and the implications under the Hong Kong Stock Exchange Listing Rules Chapter 14A concerning continuing connected transactions. The document is structured as a formal announcement to shareholders and the market about a continuing connected transaction, including compliance with reporting and announcement requirements but exempt from shareholders' approval. There is no financial statement or detailed financial report included, nor is it a report publication announcement or a certification. The content fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about connected transactions under listing rules, not a full financial report or other specific filing type.
2017-08-29 English
2017 INTERIM RESULTS ANNOUNCEMENT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2017 Interim Results Announcement' and contains detailed unaudited consolidated financial statements for the six months ended 30 June 2017, including profit and loss, financial position, segment information, notes on accounting policies, and income tax expense. It references HKAS 34 Interim Financial Reporting and includes comprehensive financial data and analysis for a period shorter than a full fiscal year. The length of the document (15,000 characters) and the presence of substantive financial statements confirm it is a financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-22 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited interim results for the six months ended 30 June 2017. It does not contain the interim results themselves, only the notification of the meeting date. The document length is only 1282 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, announcements about the timing or scheduling of report approvals are classified as Report Publication Announcements (RPA).
2017-08-10 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 July 2017
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/07/2017, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and related disclosures rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements, typical for compliance with exchange rules. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about share capital movements, fitting best under the category of Regulatory Filings (RNS). The document length is substantial and contains detailed tables, not a brief announcement or certification, so it is not a Report Publication Announcement or officer certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-08-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 June 2017
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/06/2017, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements rather than a full financial report or announcement of a report. The document is substantive and not a brief announcement or certification. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2017-07-03 English
DISCLOSEABLE TRANSACTION-LICENSE AGREEMENTS RELATING TO PATENT AND TECHNOLOGY RIGHTS
Regulatory Filings Classification · 100% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding a discloseable transaction involving license agreements related to patent and technology rights. It details the terms of the license agreements, including milestone fees, license fees, royalties, parties involved, and listing rules implications. The document is structured as a formal announcement to the stock exchange and shareholders, focusing on the transaction details and regulatory compliance under the Listing Rules. There is no financial data, earnings information, or management discussion of financial results. It is not a report, audit, or presentation but a regulatory announcement about a significant transaction. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2017-06-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.